Enzalutamide plus androgen deprivation therapy prolongs survival in men with metastatic hormone-sensitive prostate cancer

Adding abiraterone acetate plus prednisolone to standard therapy lengthens survival in non-metastatic high-risk prostate cancer

Welcome to APCCC 2021

ESMO 2021 Roundup

PARP inhibitors in prostate cancer: Case based testing and clinical decisions

OncoAlert and ecancer - ESMO 2021 Day 4

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer

OncoAlert and ecancer - ESMO 2021 Day 3

STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic renal cancer

Nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced RCC

High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer

Cabozantinib in combination with atezolizumab in patients with mCRPC